Clinical Trial Update: Post Marketing Surveillance on Safety Evaluation of POMALYST® (Pomalidomide) Treatment of Multiple Myeloma in Korea

View source ↗

Summary

Post-marketing safety surveillance study of pomalidomide (POMALYST) for multiple myeloma conducted in Korea has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Pomalyst (pomalidomide)

Snippet

Sponsor: Celgene | Conditions: Multiple Myeloma | Status: COMPLETED